Nanjing Well Pharmaceutical Group Co. Ltd. Class A

Nanjing Well Pharmaceutical Group Co. Ltd. Class A

SSSE:603351
27.77
CNY
-0.20
(-0.72%)
1.15EPS
23.65P/E
3.72BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.25
8.76
5.68
7.09
8.19
6.88
5.64
7.81
8.42
8.55
9.56
9.82
10.35
Basic EPS, GAAP
0.79
1.07
0.75
1.1
1.14
1
0.77
0.76
0.72
0.83
1.08
1.11
1.16
Free Cash Flow per Basic Share
- -
0.07
0.6
0.08
-0.13
0.07
-1.45
-1.85
-0.95
0.35
1.26
1.37
- -
Dividend per Share
0.24
0.25
0.53
0.22
0.36
0.35
0.36
0.34
0.39
0.4
0.41
0.48
0.68
Book Value per Share
2.45
3
4.53
5.44
6.27
9.5
9.95
10.21
10.93
11.7
12.57
13.26
13.53
Tangible Book Value per Share
1.99
2.55
4.09
5
5.84
8.89
9.35
9.63
10.24
10.97
11.74
12.46
12.66
Basic Weighted Avg Shares
57
57
98
98
98
128
130
133
132
135
136
136
135
Sales/Revenue/Turnover
528
499
558
694
801
881
736
1,042
1,111
1,156
1,297
1,335
1,399
Operating Margin (%)
11.59
16.29
18.42
18.89
16.71
17.83
15.55
12.37
10.89
11.99
14
14.05
14.31
Depreciation Expense
- -
17
21
26
28
34
34
43
72
72
116
133
- -
Net Income, GAAP
45
61
74
107
112
128
100
101
95
112
146
151
157
Effective Tax Rate (%)
14.67
15.76
18.57
14.52
14.68
16.88
15.08
15.65
16.32
10.15
15.64
13.7
13.4
Profit Margin (%)
8.5
12.17
13.19
15.48
13.95
14.55
13.65
9.73
8.55
9.71
11.29
11.31
11.22
Working Capital
9
13
111
143
138
624
193
42
-110
42
121
210
184
LT Debt
- -
- -
- -
- -
- -
- -
11
14
56
104
47
67
10
Total Equity
240
294
444
533
615
1,241
1,300
1,385
1,482
1,593
1,708
1,803
1,842
Return on Invested Capital (%)
- -
15.8
17.31
19.11
16.48
12.74
7.31
6.74
5.4
5.44
6.78
6.53
6.87
Return on Capital (%)
- -
17.79
16.99
19.6
17.53
12.88
7.59
7.23
6.01
6.47
7.46
7.1
7.55
Return on Common Equity (%)
- -
22.72
19.97
22.01
19.49
13.81
7.91
7.56
6.64
7.32
8.91
8.63
8.83

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
525
399
321
LT Borrowings
52
- -
- -
LT Finance Leases
15
13
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
135
135
135
Market Capitalization
3,554
3,306
3,719

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
960
759
686
Cash, Cash Equivalents & STI
438
212
174
Accounts Receivable, Net
241
240
199
Inventories
196
214
212
Total Current Liabilities
691
600
503
Payables & Accruals
- -
- -
- -
ST Debt
525
399
321
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.66%
6.77%
5.54%
Free Cash Flow
-129.6%
22.76%
9.23%
Net Income, GAAP
11.07%
9.27%
3.11%
Sales/Revenue/Turnover
11.26%
13.47%
2.95%
Total Cash Common Dividend
34.34%
6.91%
16.99%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
330
358
312
296
1,297
2025
350
324
- -
317
1,335
2026
356
383
342
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.26
0.34
0.25
0.25
1.08
2025
0.27
0.27
- -
0.27
1.11
2026
0.28
0.29
0.32
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.34
0.03
0.03
0.41
2025
0.02
0.42
- -
0.02
0.48
2026
0.03
0.62
0.01
- -
- -

Company Description

CEO
Ren Rong Wu
Full Time Employees
718
Sector
Process industries
Industry
Chemicals: major diversified
Address
Building 5, 64 Suning Avenue Nanjing JS China 210042
IPO Date
Jan 30, 2019
Website
wellnj.com
Business
Nanjing Well Pharmaceutical Group Co Ltd (603351:SHH), formerly Nanjing Well Pharmaceutical Co Ltd, engages principally in the research, development, manufacturing and sales of pharmaceutical auxiliary materials, synthetic lubricating base oils and pesticide additives; its core pharmaceutical excipients portfolio encompasses Polysorbate (Tween) series, Span series (fatty acid sorbitan esters), Polyethylene Glycol series, Poloxamer series and Propylene Glycol for solid, semi-solid and liquid preparations including injections, eye drops, microspheres, liposomes, suppositories, ointments and tablets, alongside active pharmaceutical ingredients (APIs), chiral intermediates, advanced intermediates, veterinary drug intermediates, probiotics, anesthetic preparations, emulsifying/solubilizing agents, microencapsulation products, solvents, suspending/viscosity increasing agents and tablet binders/fillers; the company also produces new pesticide adjuvants and animal health care products. Nanjing Well Pharmaceutical Group Co Ltd, founded in 2000 and headquartered at Block 5, R&D Zone 5, Xuzhuang Software Park, 64 Suning Avenue, Xuanwu District, Nanjing 210042, China, operates primarily in the domestic Chinese market with annual pharmaceutical excipient sales exceeding 10,000 tons and long-term supply relationships with over 1,000 pharmaceutical enterprises including Johnson & Johnson, GSK, Novartis and Bayer; subsidiaries include Nanjing Well Pharmaceutical Technology Co Ltd, a new R&D and manufacturing center in Nanjing Jiangbei New Material Science and Technology Park with 15 synthetic lines and 7 GMP packaging lines for over 20,000 tons annual output of excipients and APIs, Nanjing Well Biomaterial Co Ltd focused on agricultural surfactants, Nanjing Well Biotechnology Co Ltd, Yangzhou Weier Biotechnology Co Ltd and Nanjing Well Materials Science and Technology Research Institute Co Ltd. The company changed its name to Nanjing Well Pharmaceutical Group Co Ltd in April 2020 to reflect its expanded group structure and maintains over 100 invention patents including 11 PCT applications, with certain excipients holding CEP and US FDA DMF filings; it employs 711 people generating trailing 12-month revenue of CNY1.28 billion and net income of CNY140.29 million as of late 2024.